Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma

This study is testing whether adding camrelizumab — an immunotherapy drug that helps the immune system attack cancer — to standard chemotherapy and radiation can improve outcomes for people with locally advanced nasopharyngeal carcinoma (cancer at the back of the nose and throat). **You may be eligible if...** - You have been diagnosed with nasopharyngeal carcinoma, confirmed by biopsy - Your cancer is stage III or IVA (locally advanced but not yet spread to distant organs) - You are in reasonably good health (ECOG ≤ 1) - You are between 18 and 70 years old - Your blood counts, liver function, and kidney function are adequate - You are willing to use contraception for 1 year after the last dose **You may NOT be eligible if...** - You have active hepatitis B or C - You have active autoimmune disease requiring treatment - You are taking systemic corticosteroids - You have had prior treatment for nasopharyngeal cancer - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.